RECURSION PHARMACEUTICALS, INC.
RXRXNasdaqHealthcare · Biological Products, (No Diagnostic Substances) · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | $74.7M | $58.8M | $44.6M | $39.8M | $10.2M | $4.0M |
| Operating income | −$648.1M | −$479.0M | −$350.1M | −$245.7M | −$182.8M | −$84.6M |
| Net income | −$644.8M | −$463.7M | −$328.1M | −$239.5M | −$186.5M | −$87.0M |
| Total assets | $1.47B | $1.45B | $653.7M | $701.3M | $610.3M | $298.6M |
| Total liabilities | $343.3M | $413.8M | $190.3M | $215.5M | $67.4M | $56.6M |
| Equity | $1.13B | $1.03B | $463.4M | $485.8M | $542.9M | −$206.3M |
| EPS (diluted) | $-1.44 | $-1.69 | $-1.58 | $-1.36 | $-1.49 | $-3.99 |
| Shares out. | 528.2M | 396.8M | 234.3M | 191.0M | 170.3M | 22.3M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- −867.9%
- Net margin
- −863.4%
- Return on equity
- −57.0%
- Return on assets
- −43.7%
- Return on capital (ROCE)
- −48.9%
- Liabilities / assets
- 23.3%
- Debt / equity
- 0.30×
- Book value / share
- $2.14
- Revenue growth (YoY)
- 26.9%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- -1.13distress
- Accruals / assets
- −18.5%clean
- Piotroski F-Score
- 4/9mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →
Signs
● 1 severe● 3 warning● 3 good- Altman Z″ in the distress zone
- Operating losses (negative operating margin)
- Reported a net loss
- Negative operating cash flow
- Revenue is growing year-over-year
- Conservative leverage (liabilities < 50% of assets)
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Clinical trials
ClinicalTrials.gov · ongoing · next readout first- Phase 1/2Recruitingreadout ~2027-06Evaluate REC-4881 in Participants With Familial Adenomatous Polyposis (FAP)
- Phase 1/2Recruitingreadout ~2028-10-30A Study of REC-1245 in Participants With Unresectable, Locally Advanced, or Metastatic Cancer
Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- State Street CorpPassive (13G)May 12, 2026
- Blackrock, Inc.Passive (13G)Apr 24, 2026
- Vanguard Group IncPassive (13G)Mar 27, 2026
- Baillie Gifford & CoPassive (13G)Feb 5, 2026
- Ark Investment Management LlcPassive (13G)Feb 3, 2026
- Mubadala Investment Co PjscActivist (13D)Dec 23, 2025
- Ra Capital Management, L.P.Passive (13G)Feb 14, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 184.4M | 13.3 | +7.7% |
| Apr 30, 2026 | 171.3M | 14.8 | -1.8% |
| Apr 15, 2026 | 174.4M | 17.1 | +0.3% |
| Mar 31, 2026 | 173.9M | 12.3 | -0.1% |
| Mar 13, 2026 | 174.1M | 12.7 | +3.3% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Results of operations · Regulation FD disclosureMay 6, 2026
- Director / officer change · Regulation FD disclosureApr 30, 2026
- Director / officer change · Regulation FD disclosureMar 25, 2026
- Results of operations · Regulation FD disclosureFeb 25, 2026
- Regulation FD disclosureJan 12, 2026
- Other material eventDec 8, 2025
- Other material eventNov 26, 2025
- Results of operations · Director / officer change · Regulation FD disclosureNov 5, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Event-driven situations (3)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.